About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
BAY-6035 A potent, peptide-competitive chemical probe for SMYD3This probe is available from Sigma, Tocris and Cayman Chemical. For any inquiries please contact proberequests@thesgc.org.group newOverview BAY-6035 BAY-444 A collaboration between Bayer AG and the SGC has resulted in the discovery of BAY-6035, a potent, peptide-competitive chemical probe for SMYD3. BAY-6035 has a unique chemotype relative to the published SMYD3 inhibitor, EPZ031686. BAY-6035 inhibits in vitro methylation of MEKK2 peptide with IC50 = 88 nM and has more than 100-fold selectivity over other histone methyltransferases. BAY-6035 inhibits the methylation of MEKK2 in cells with IC50 = 70 nM. A control compound, BAY-444, has also been developed. BAY-444 inhibits the in vitro methylation of MEKK2 with IC50 = 23 micromolar. https://doi.org/10.1177/24725552211019409 Properties BAY-6035 BAY-444 (negative control) Physical and chemical properties for BAY-6035 Molecular weight 396.2 Molecular formula C22H28N4O3 IUPAC name 6-((3-aza-bicyclo[3.1.0]hexan-3-yl)-formyl)-10-((2-cyclopropyl-ethylamino)-formyl)-5-methyl-2,6-diaza-bicyclo[5.4.0]undeca-1(7),8,10-trien-3-one MollogP 2.011 PSA 66.79 No. of chiral centres 3 No. of rotatable bonds 7 No. of hydrogen bond acceptors 6 No. of hydrogen bond donors 2 Physical and chemical properties for BAY-444 (Negative Control) Molecular weight 410.2 Molecular formula C23H30N4O3 IUPAC name 6-((3-aza-bicyclo[3.1.0]hexan-3-yl)-formyl)-10-(((2-cyclopropyl-ethyl)-methyl-amino)-formyl)-5-methyl-2,6-diaza-bicyclo[5.4.0]undeca-1(7),8,10-trien-3-one MollogP 2.208 PSA 58.66 No. of chiral centres 3 No. of rotatable bonds 7 No. of hydrogen bond acceptors 6 No. of hydrogen bond donors 1 SMILES: BAY-6035: C[C@H]1CC(Nc2cc(ccc2N1C(N1CC2CC2C1)=O)C(NCCC1CC1)=O)=O BAY-444: C[C@@H]1CC(Nc2cc(ccc2N1C(N1CC2CC2C1)=O)C(N(C)CCC1CC1)=O)=O InChI: BAY-6035: InChI=1S/C22H28N4O3/c1-13-8-20(27)24-18-10-15(21(28)23-7-6-14-2-3-14)4-5-19(18)26(13)22(29)25-11-16-9-17(16)12-25/h4-5,10,13-14,16-17H,2-3,6-9,11-12H2,1H3,(H,23,28)(H,24,27)/t13-,16?,17?/m0/s1 BAY-444: InChI=1S/C23H30N4O3/c1-14-9-21(28)24-19-11-16(22(29)25(2)8-7-15-3-4-15)5-6-20(19)27(14)23(30)26-12-17-10-18(17)13-26/h5-6,11,14-15,17-18H,3-4,7-10,12-13H2,1-2H3,(H,24,28)/t14-,17?,18?/m1/s1) InChIKey: BAY-6035: CKFRXCBNKKOFGO-IGEOTXOUSA-N BAY-444: FNTARNKIMWWTFZ-RWBZWWBESA-N